Background: Human leukocyte antigen (HLA) Class I A, B, and C are MHC class I proteins that present peptides to cytotoxic T cells and are expressed on all nucleated cells of vertebrates.  The peptides are generated by the proteasome from intracellular proteins. In healthy cells these peptides will consist of self proteins but from infected cells some peptides will be from foreign proteins causing antigen-specific cytotoxic T cells to become activated and kill the cell. Certain viruses and tumors can downregulate HLA expression, avoiding detection by cytotoxic T cells that could recognize peptides from viral proteins or mutated proteins of cancer cells.

Validation: Each lot of conjugated HLA Class I antibody is quality control tested by MIBIscope™ analysis of stained tissue microarrays using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of HLA Class I antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Coulie, P.G. et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14(2):135-46.
• Antoniou AN, Powis SJ, Elliott T. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol. 2003; 15:75–81.

* Conjugate tested on human tissue.